Bellerophon Therapeutics, Inc.
BLPHDelisted Dec 27, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001600132
Bellerophon Therapeutics, Inc. was delisted on Dec 27, 2023; its insiders filed their last Form 4 on Oct 16, 2023; 22 institutions reported holding it in 13F filings for Q3 2023, worth $506.6K in total; no superinvestor held it.
13F holders, Q1 2024
Institutional positions in Bellerophon Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
BLPH is no longer listed, and 13F filings after Q3 2023 list far fewer holders. See Q3 2023
- Institutional holders
- 0
- −2 vs. Q4 2023
- Shares held
- 0
- −209.6K (−100.0%) vs. Q4 2023
- Total value
- $0
- −$6.37K (−100.0%) vs. Q4 2023
- New holders
- 0
- 0 more added
- Sold out
- 2
- 0 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BLPH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 2 | $6.37K |
| Q3 2023 | 22 | $506.6K |
| Q2 2023 | 23 | $824.9K |
| Q1 2023 | 19 | $27.9M |
| Q4 2022 | 25 | $832.7K |
| Q3 2022 | 19 | $1.18M |
| Q2 2022 | 19 | $1.40M |
| Q1 2022 | 22 | $2.68M |
| Q4 2021 | 22 | $3.82M |
| Q3 2021 | 22 | $4.81M |
| Q2 2021 | 27 | $6.34M |
| Q1 2021 | 39 | $10.9M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Bellerophon Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −199,600−100.0% | Sold out |
| Raymond James & Associates | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |